OmniAb Past Earnings Performance

Past criteria checks 0/6

OmniAb's earnings have been declining at an average annual rate of -21%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 26.4% per year.

Key information

-21.0%

Earnings growth rate

-94.0%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate26.4%
Return on equity-16.1%
Net Margin-148.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade

Mar 26
Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade

Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)

Feb 28
Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)

OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price

Jan 15
OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price

Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares

Nov 11
Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares

Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts

Aug 13
Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts

OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially

May 14
OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially

Revenue & Expenses Breakdown
Beta

How OmniAb makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:OABI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2334-513852
30 Sep 2365-303951
30 Jun 2366-273750
31 Mar 2366-223347
31 Dec 2259-222944
30 Sep 2239-322540
30 Jun 2238-281941
31 Mar 2238-251939
31 Dec 2135-271937
30 Sep 2133-241636
31 Dec 2023-181025
31 Dec 1918-14913

Quality Earnings: OABI is currently unprofitable.

Growing Profit Margin: OABI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OABI is unprofitable, and losses have increased over the past 5 years at a rate of 21% per year.

Accelerating Growth: Unable to compare OABI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OABI is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.3%).


Return on Equity

High ROE: OABI has a negative Return on Equity (-16.09%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.